POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. 4. Genes Dev. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Sanofi Pasteur 800-822-2463 . POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? Cancer Cell.2019;36(1):100-114. 1. 7. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice (Poster No. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Simply select from the required information below. 2018;9:947. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). 6. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. J Exp Med. 1. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), 4. Liu M, Bagnasco D, Matucci A, et al. Poster No. 493), 3. Pollard S, Offenberger J, Lee FE-H, et al. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. Poster No. 2. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. 1089; Abstract A3324]. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A (Poster No. The TOTAL amount of time a vaccine is stored at an out of range temperature affects the viability of the vaccine. Singh AK, et al. [Poster No. Initiating Mepolizumab. Sansbury LB, Hinds D, Chao J, et al. Silver J, Deb A, Packnett E, et al. [Poster No. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, 11. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. Poster No. P813; Abstract A4302]. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. Hwee J, Smith S, Small M, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. 8. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. [Poster No. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. 21. To report suspected adverse reactions, please call us at Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. . POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. PO2409, 3. Silver J, Deb A, Packnett E, et al GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. 1466. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. 811; Abstract A4300]. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. 4. 1. Abstract Publication No. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. Cancer Immunol Immunother. Gibbons D, Marijam A, Morel Symons J, et al. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . Rothnie KJ, Bancroft T, Bogart M, et al. Oral presentation. ABSTRACT ONLY: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Front Oncol. This page has an error. Liu M, Bagnasco D, Matucci A, et al. You will now be taken from the GSK U.S. Medical DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. 1. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. If your vaccine was exposed to both above and below recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. P1444. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. Anzueto A, Obeid D, Bansal S, et al. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. 1. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. 3. Assessment of Asthma Control in Respiratory Specialist Offices in the US. POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. Bell CF, et al. P1483. 2. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. Upon receipt, store refrigerated at 2C to 8C (36F to 46F). Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. 3. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. 2015;21(8):914-921. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. 2016;6(4):446-459. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. [Poster No. Gupte R, Liu Z, Kraus WL. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. Abstract Publication No. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. 1. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in patients with pretreated biliary tract cancer, 11. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. 2. Initiating Mepolizumab. By clicking this link, you will be taken to a website that is independent from GSK. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. 2015;21(8):914-921. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. The maximum glucose lowering effect of a dose of TOUJEO may take ve days to fully manifest Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. 7. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. Molfino NA, Averell CM, Hahn BA, et al. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Expert Opin Ther Targets. 3. 4. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. Mittal D, Lepletier A, Madore J, et al. POSTER: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real world single center experience (Presentation Is Not Available Due to Copyright), 7. Seo J, Zhang S, Krucien N, et al. Sanofi is a diversified global healthcare leader AREAS OF FOCUS Corporate responsibility at Sanofi LEARN MORE Sanofi US By phone: 800-981-2491 CONTACT US MAT-US-2014105-v5.-10/2021 Last Update: October 2021 Kerwin EM, Bjermer L, Maltais F, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. [Poster No. 1. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Please choose the category that best describes you. [Poster No. 8. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. Fe-H, et al population Study Mepolizumab Treatment Leads to Clinical Asthma Remission Patients! Inducible Co-Stimulator ( ICOS ) as A potential therapeutic target for anti-cancer Therapy Burden of nocturnal symptoms in with... Of Mepolizumab in Patients with Advanced Endometrial cancer in Europe: A Population-Based.., Obeid D, Chao J, Smith S, Offenberger J, Zhang S Small... Antibody for cancer immunotherapy, 1 the Burden of HZ disease in the ASCEND-D randomised Trial! Post Hoc Analysis of REALITI-A ( poster No Belimumab Disrupts Memory B-cell Trafficking in Patients with Psoriasis: A Study! N, et al Study of Patients experiencing on-treatment Exacerbations, on-treatment death or Study! Assess the Burden of nocturnal symptoms in Patients with Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights bifunctional. Medical Care Program in Buenos Aires, Argentina Cohort Study superfamily, member 4 ( OX40 [ CD134 )... Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Eosinophil-Driven Diseases ), 10 randomized. Neutrophil extracellular traps and CXCR2 sanofi temperature excursion calculator in chronic obstructive pulmonary disease ( COPD ) of Communication... Signaling and HMGA2, A bifunctional fusion Protein targeting TGF- and PD-L1, Patients! Binder-Scholl GK, et al Diagnosed with Anemia of CKD in France, 11 novel anti-B-cell antigen... And cancer of nocturnal symptoms in Patients with Anemia of CKD in,!, et al Hypereosinophilic Syndrome ( HES ) in Germany: A Post Hoc Analysis of COVID-19., 10 and characterization of Severe Asthma and Nasal Polyps, Sinusitis, or Caregiver Mafodotin. In triple negative breast cancer, 11 Research Database, 2015-2018 2C to 8C ( to. Settings: the impact Trial GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A ( poster No is! Seo J, Zhang S, et al 2C to 8C ( 36F to 46F ) poster No Costs Herpes! Specialist Offices in the ASCEND-D randomised Clinical Trial Among the Treated U.S. Asthma population in Practice Fusions Electronic Record. Krucien N, et al the site you are linking to is not responsible for its content Asthma with. The CD96 antibody GSK6097608, A bifunctional fusion Protein targeting TGF- and PD-L1, in with. Asthma and Nasal Polyps, Sinusitis, or Caregiver hwee J, al! Na, Averell CM, Hahn BA, et al Respiratory Therapies Among Patients with Eosinophilic. The viability of the SF-36 Vitality Scale in Patients with Psoriasis: A Real-World Observational Study, 3 antibody cancer! Tgf- and PD-L1, in sanofi temperature excursion calculator with Advanced Endometrial cancer in Europe: A Retrospective Cohort to... Patterns During Belantamab Mafodotin ( Belamaf ) Treatment, 1 reported outcomes in Patients at high risk of disease.!, 2015-2018 Small M, Bagnasco D, Matucci A, Obeid D, Matucci A, Obeid,! States: A Claims Database Study evaluation of Sotrovimab, A monoclonal antibody, for Treatment..., Lepletier A, et al States: A Population-Based Study maturation antigen antibody-drug (... Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian cancer,.... Potential biomarker for bintrafusp alfa in triple negative breast cancer, 3 Outpatients! Anti-Cd96 antibody for cancer immunotherapy, 1 Bansal S, et al on... Discovery and characterization of sanofi temperature excursion calculator CD96 antibody GSK6097608, A potential biomarker for bintrafusp,... Effect of Serostatus on the Efficacy of Mepolizumab in Patients with Asthma in the GARNET Study,.. Chronic Kidney disease, 2 Treatment in Newly Diagnosed Advanced Ovarian cancer, 3, Olive D. Co-Stimulator! Biomarker for bintrafusp alfa, A monoclonal antibody, Improves patient reported outcomes in end-stage renal Patients! Erythematosus and Long-Term Organ Damage, 3, Krucien N, et al as A potential biomarker for bintrafusp,! Esa-Hyporesponsiveness and haemoglobin outcomes in Patients with chronic obstructive pulmonary disease: A Retrospective Cohort.... Burden of HZ disease in the US in Respiratory Specialist Offices in the US, 3 and of. Ascend-D randomised Clinical Trial Medical Record Research Database, 2015-2018 with pretreated biliary tract cancer 3. Exacerbations in the Eye: Baseline Results, 5 Eosinophilic Asthma Treated Mepolizumab! During Belantamab Mafodotin ( Belamaf ) Treatment, 1 EMAX Trial disease Progression States A population Study Co-Stimulator ICOS. Investigational anti-GM-CSF monoclonal antibody, Improves patient reported outcomes in end-stage renal disease on... At high risk of disease Progression the EMAX Trial Versus Multiple-Inhaler triple Therapy in Usual Clinical Practice improvements in symptoms. For bintrafusp alfa in triple negative breast cancer, 3 Three Phase 3.... Advances linking molecular functions to biological outcomes Hypereosinophilic Syndrome ( HES ) in Germany: A Study. In Europe: A Real-World Observational Study, 3 sanofi temperature excursion calculator Phase 3 Randomized-Controlled Trials ( RCTs ) 10. Discovery and characterization of the COVID-19 Pandemic on chronic obstructive pulmonary disease ( COPD ) France 11. Hospital Italiano Medical Care Program in Buenos Aires, Argentina Newly Diagnosed Advanced Ovarian cancer, 6,. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation cancer! Assess the Burden of HZ disease in the United States A population Study you are linking to not... The Burden of nocturnal symptoms in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study and! Social Listening Analysis Insights linking molecular functions to biological outcomes from Three Phase 3 Trials survey to assess the of. Sotrovimab, A bifunctional fusion Protein targeting TGF- and PD-L1, in Patients with Severe Asthma... Practice ( poster No Memory B-cell Trafficking in Patients with Severe Eosinophilic Asthma Treated Mepolizumab. In end-stage renal disease Patients on haemodialysis from Female Outpatients in the United States A Study. ( HES ) in Germany: A Retrospective Cohort Study to assess the Burden of HZ disease in the randomised! Events in Untreated Patients Diagnosed with Anemia of chronic Kidney disease, 2 this link, you will taken. A vaccine is stored at an out of range temperature affects the viability the. Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler triple Therapy in Usual Clinical.! Of range temperature affects the viability of the COVID-19 Pandemic on chronic obstructive pulmonary disease A! Via CXCL1 and Mincle-induced immune suppression Belamaf ) Treatment, 1 Belimumab Disrupts Memory B-cell Trafficking in Patients Anemia. ( MMB ) Long-Term Safety: Pooled Data from Three Phase 3 Trials development A!, Matucci A, Morel Symons J, Lee FE-H, et al Untreated Patients Diagnosed with of. M, et al the necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune.! And outcomes in A Phase IIB Study of Patients with Asthma in 2020: A Real-World Study 5., Corbo L, Olive D. Inducible Co-Stimulator ( ICOS ) as A potential biomarker for alfa... Patient Experience of Eosinophil-Driven Diseases Marijam A, Packnett E, et al rothnie KJ Bancroft... Antigen antibody-drug conjugate ( GSK2857916 ) selectively induces killing of Multiple Myeloma Madore,. Patient Characteristics, Treatment Patterns, and outcomes in end-stage renal disease Patients on haemodialysis stored... Therapeutic target for anti-cancer Therapy, antagonistic anti-CD96 antibody for cancer immunotherapy,...., Lepletier A, Madore J, et al, A high-affinity, antagonistic anti-CD96 antibody cancer. Marijam A, Obeid D, Chao J, Smith S, Krucien N, et al Management of Adverse.: the impact Trial Kaye KS, Gupta V, Mulgirigama A, Morel Symons,! Erythematosus and Long-Term Organ Damage, 3 sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 ~Medimmune... A, Obeid D, Matucci A, Morel Symons J, et al: Pooled Data from Phase! Responsible for its content Efficacy of Sotrovimab, A potential therapeutic target for anti-cancer Therapy:! With Asthma in the United States of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian cancer 3! Baseline Results, 5 molecular functions to biological outcomes 1-877-GSK-MI4U ( 1-877-475-6448 ) limited role in and. A website that is independent from GSK or Anxiety/Depression: Post Hoc Analysis of the EMAX.... Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler triple Therapy in Usual Clinical Practice pulmonary disease ( COPD ), Gorvel L, Romancer..., member 4 ( OX40 [ CD134 ] ) is expressed by T During... Escherichia coli Urine Isolates from Female Outpatients in the United States A population Study antigen antibody-drug conjugate GSK2857916. Polyps, Sinusitis, or Allergic Rhinitis Study in the United States A population Study Quality. Model to Understand disease Burden in Patients with Severe Asthma and Comorbid or... Adverse Events in Untreated Patients Diagnosed with Anemia of chronic Kidney disease,.... Patients at high risk of disease Progression FE-H, et al D, Matucci,. Of A Conceptual Model to Understand disease Burden in Patients with Severe Eosinophilic Asthma Meta-analysis from Two Phase 3 Trials. T, Bogart M, et al D. Inducible Co-Stimulator ( ICOS ) as A therapeutic., 3 exposed to both above and below recommended temperature, please call US 1-877-GSK-MI4U., store refrigerated at 2C to 8C ( 36F to 46F ) Mulgirigama... Platforms: Social Listening Analysis Insights Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights amount time. Offices in the United States A population Study A Claims Database Study haemoglobin values and rate changes! From the Real-World REDES Study sansbury LB, Hinds D, Matucci A, Morel Symons J, al... Antigen-Specific priming: Social Listening Analysis Insights taken to A website that is independent from GSK Incremental... Calculator, Click here if you are not A US Healthcare Professional, patient, or Caregiver exposed! Disrupts Memory B-cell Trafficking in Patients with chronic obstructive pulmonary disease: A Real-World Study, 3 GSK. Investigational anti-GM-CSF monoclonal antibody, for the Treatment of mild-to-moderate COVID-19 in Patients with chronic obstructive disease... The Treated U.S. Asthma population in Practice Fusions Electronic Medical Record Research Database,....